TEL: 044-952-0102


Competitive Strategies in an Era of Consolidation & Disruptive Technologies

発行 BioInformatics, LLC 商品コード 305955
出版日 ページ情報 英文 100 Pages
納期: 即日から翌営業日
本日の銀行送金レート: 1USD=112.09円で換算しております。
Back to Top
統合&ディスラプティブ技術の時代における競合戦略 Competitive Strategies in an Era of Consolidation & Disruptive Technologies
出版日: 2014年08月14日 ページ情報: 英文 100 Pages



  • この買収に応えてその他のサプライヤーは合併すべきか?
  • 中核市場を守るため、競合企業は周辺市場から撤退すべきか?
  • 競合企業の間でさらなるアライアンスがあるか?
  • 小規模のライフサイエンス企業は市場へどのように新技術をもたらすことが出来るか?
  • 大手企業がオーダーメイド医療/臨床診断へ積極的に進出した場合、引き続き基礎研究に重点を置くサプライヤーに就職口はあるか?


  • 「攻撃」戦略:新たに合併された企業を、合併の動揺・混乱に気を取られている際に攻撃する
  • 「マグネット」戦略:合併のショック状態にある間に、合併した競合企業の最も優秀な人々を惹きつけ、雇用するために「マグネット戦略」を構築する
  • 「脅威」戦略:内部変化を活性化させるため、企業の生き残りにとっての脅威を用いる
  • 「アライアンス」戦略:成長を刺激するため、合併の代わりに複数のアライアンス、ライセンシングもしくはジョイントベンチャーを用いる
  • 「迅速なM&A」戦略:新技術を獲得し、チャネルアクセスを向上または製品ラインを拡張するために、企業の迅速なM&Aを計画し実行する
  • 「複合」戦略:成長・採算性を最大化すると同時に、上記の二つ以上の戦略を用いて複合戦略を構築する



Product Code: 14-006

BioInformatics LLC, the leading research and advisory firm serving the life science tools market, will conduct an unprecedented analysis of competitive strategies in an era of flat growth, Thermo Fisher Scientific's acquisition of Life Technologies, other mergers, and disruptive technologies. This prospectus highlights the objectives and methodology of the research effort and the analysis and actionable strategies that will be delivered in the final report.

The Situation

The life science tools market has been in a near constant state of flux over the past five years as established companies have merged or been acquired, new companies are founded, and emerging technologies (such as next generation sequencing) disrupt long established markets and create new opportunities. All of this change is layered over constrained research funding in the United States and Europe and increased levels of life science spending and investment in Asia.

This market turbulence came to a head when in April 2013 Thermo Fisher Scientific (TMO) announced that it planned to acquire Life Technologies (LIFE) in a $13.6 billion transaction. On February 3, 2014, the deal closed and a $17 billion company focused on the life sciences emerged. Completion of the transaction followed the receipt of all the required regulatory approvals and included the sale of the cell culture (sera and media), gene modulation and magnetic beads businesses to GE Healthcare for $1.07 billion. This constant state of disruption can be confusing for customers, challenging for the merging companies, and (if played appropriately) moments of opportunity for competitors.

Now what?

Life science tools companies have had a year to determine how to compete in this new market that is dominated by one very large competitor with enhanced scale, impressive channel access, and the breadth and depth of capabilities to meet customer needs in research, specialty diagnostics and applied markets. Mergers are one way for companies to respond to external market conditions that reward scale, size and cost-effectiveness. The prevailing question that this report seeks to answer is: How should life science tools companies compete in this new market environment?

  • Should other suppliers merge in response to this acquisition?
  • Will competitors retreat from peripheral markets in order to defend core markets?
  • Will there be more alliances among competitors?
  • How can smaller life science companies bring new technologies to market?
  • If major players move aggressively into personalized medicine/clinical diagnostics are there openings for suppliers who remain focused on basic research?

In light of these questions, which business strategies might be implemented?

For example:

  • "Attack" Strategy: Attack newly merged entities when they are distracted by their mergers' turmoil and confusion.
  • "Magnet" Strategy: Create a "magnet strategy" to attract and hire your merging competitors' best people while their companies are in a state of merger shock.
  • "Threat" Strategy: Use the threat to your firm's survival to jump-start internal change.
  • "Alliance" Strategy: Use multiple alliances, networks, licensing, or joint ventures - instead of mergers - to fuel growth.
  • "Fast-track M&A" Strategy: Plan and execute your firm's fast-track mergers and acquisitions to acquire new technology, increase channel access or extend product lines.
  • "Composite" Strategy: Create a composite strategy by using two or more of the above strategies simultaneously to maximize growth and profitability.

The purpose of this study is to take the pulse of the life science ecosystem to discern the effects of recent mergers, overall low growth, and disruptive technologies on suppliers and customers.

Research Objectives

  • Understand if and how competitors are adjusting their business strategies in light of recent transactions and current market conditions (e.g., pharma consolidation).
  • Ascertain how customers perceive the current life science research landscape - suppliers, channel access, research funding, research initiatives (e.g., BRAIN Initiative), science policy (e.g., translational research), and their adoption of new technology.
  • Present strategies for competing successfully in the turbulent life science market.


Mega-mergers tend to weed out marginal competitors and create opportunities for those astute enough to know what is happening around them. Multi-sponsor market research enables companies to quickly gain competitive advantage through insights that support strategic decisionmaking - at a fraction of the cost of a custom research project. Multi-sponsor research is the concept of sharing the costs and the results with a select group of market participants at a significant discount months before the results are released for general sale.

Start-Up Time

BioInformatics LLC has a multidisciplinary team of scientists, industry veterans and market research experts who will begin work upon receipt of your Sponsorship Agreement.


BioInformatics LLC has unmatched expertise in the life science market and has delivered market studies to more than 500 unique firms.


BioInformatics LLC multi-sponsor research projects are unbiased and provide a fresh perspective on your strategies.


There is no need for pre-publication sponsors to disrupt their routine activities. BioInformatics LLC will perform all aspects of the research and deliver the final report within the required timeframe.

Cost Control

To commission a private study of similar scale and scope would cost approximately $80,000 to $100,000 USD.

Table of Contents

  • Section 1: Executive summary and overview
  • Section 2: Competitor strategies and market analysis
  • Section 3: Customer perceptions and experiences
  • Section 4: Competitive response and strategy recommendations
  • Section 5: Study methodology
  • Section 6: Additional data analysis, including verbatim comments from customers

Back to Top